Diagnostic and Psychometric Validation of the FRENCH HELP Scale in Hyperemesis Gravidarum (French-HELP)
Severe forms of nausea and vomiting of pregnancy (NVP) are classified as hyperemesis gravidarum (HG). NVP is debilitating in approximately 35% of women impairing daily life and professional activities while negatively affecting family relationships. In 0.3% to 3.6% of pregnancies, the vomiting is intractable and represents the leading cause of hospitalization during the first trimester. Severity of symptoms can sometimes lead women to consider terminating the pregnancy or to decide against future pregnancies.
The most widely used tool for assessing NVP and HG is the PUQE score; it asks three questions regarding nausea, vomiting, and retching, and is scored from 1 to 15. A score of ≥13 classifies NVP as severe. However, the PUQE score does not include questions regarding quality of life, which is a key determinant of HG.
An international definition (the Windsor definition of HG) has been developed, extending beyond mere digestive symptoms. This definition includes: symptom onset in early pregnancy (before 16 weeks of gestation); severe nausea or vomiting; an inability to eat or drink normally; and significant limitation of daily activities or signs of dehydration. This definition aligns better with the full spectrum of symptoms associated with this condition. The US-based Hyperemesis Education and Research (HER) Foundation developed the HELP Score to better assess nausea and vomiting of pregnancy (NVP), particularly severe cases. The tool includes questions regarding the intensity of nausea and vomiting, along with nine additional questions covering hydration, nutrition, treatments and their efficacy, and quality of life. The HELP score ranges from 0 to 60, with scores of 33 to 60 classifying patients as severe; this offers greater scope for assessing levels of severity, and improvement, compared to the PUQE score, which is calculated on a 15-point scale with only 3 points allocated to the severity category.
The HELP score has proved more effective than the PUQE score at identifying patients with severe symptoms requiring intervention, in a study with several methodological limitations, such as reliance on an online questionnaire and a failure to adhere to diagnostic validation standards. Nevertheless, the lack of robust evidence warrants further research using more rigorous methodology to confirm the value of this scoring system.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Stephanie Huberlant
- 전화번호: 04 66 68 32 20
- 이메일: stephanie.huberlant@chu-nimes.fr
연구 장소
-
-
-
Alès, 프랑스
- Centre Hospitalier Alès-Cévennes
-
연락하다:
- Jeanne-Claire SIX
- 전화번호: 04 66 78 32 21
- 이메일: dr.six@ch-ales.fr
-
Béziers, 프랑스
- CH de Béziers
-
연락하다:
- Samantha HUET
- 전화번호: 04 67 35 76 07
- 이메일: samantha.huet@ch-beziers.fr
-
Mende, 프랑스
- CH de Mende
-
연락하다:
- Agnès PREVOST-FEREY
- 이메일: agnesprevostferey@ch-mende.fr
-
Montpellier, 프랑스
- CHU de Montpellier
-
연락하다:
- Philippe DERUELLE
- 전화번호: 04 67 33 64 86
- 이메일: p-deruelle@chu-montpellier.fr
-
Nîmes, 프랑스, 30029
- CHU de Nîmes
-
연락하다:
- Anissa Megzari
- 전화번호: 04.66.68.42.36
- 이메일: drc@chu-nimes.fr
-
Sète, 프랑스
- CH de Sète
-
연락하다:
- Angela MORARU
- 전화번호: 04 67 46 57 57
- 이메일: amoraru@ch-bassindethau.fr
-
Toulouse, 프랑스
- CHU de Toulouse
-
연락하다:
- Laure CONNAN
- 전화번호: 5 67 77 12 33
- 이메일: connan.l@chu-toulouse.fr
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- The patient must be a member or beneficiary of a health insurance plan
- Pregnant woman with nausea or vomiting that began during the first trimester of pregnancy (before 16 weeks of gestation) with no other identifiable cause.
- Oral consent given by the participant
Exclusion Criteria:
- The subject is in a period of exclusion determined by a previous study
- The subject unable to provide consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Presence of a secondary cause for nausea and vomiting (hepatitis, pancreatitis, atypical forms of appendicitis, pyelonephritis, adnexal torsion, hyperthyroidism, or chronic treatments known to induce vomiting).
- Presence of any pre-existing medical condition or situation that could cause vomiting (restrictive bariatric surgery, eating disorders).
- Inability to complete the questionnaires (lack of French language comprehension, illiteracy, intellectual disability, etc.).
- Patient enrolled in a study evaluating a treatment intended to address nausea and vomiting.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Women with HG
|
Evaluation of intensity of nausea and vomiting, covering hydration, diet, treatments and their effectiveness, and quality of life.
The HELP score ranges from 0 to 60-with scores of 33 to 60 classifying patients as severe
|
|
Women with severe HG
|
Evaluation of intensity of nausea and vomiting, covering hydration, diet, treatments and their effectiveness, and quality of life.
The HELP score ranges from 0 to 60-with scores of 33 to 60 classifying patients as severe
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Area under the curve for the FRENCH HELP score to diagnose hyperemesis gravidarum
기간: Month 21
|
Month 21
|
|
Area under the curve for the PUQE score to diagnose hyperemesis gravidarum
기간: Month 21
|
Month 21
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area under the curve for the FRENCH HELP score to diagnose severe hyperemesis gravidarum
기간: Month 21
|
Month 21
|
|
|
Area under the curve for the PUQE score to diagnose severe hyperemesis gravidarum
기간: Month 21
|
Month 21
|
|
|
Discordance rate between FRENCH HELP and PUQE
기간: Month 21
|
Percentage of women reclassified as severe using the HELP score who were not classified as such using the PUQE score
|
Month 21
|
|
Rate of women whose management would have been altered by using the HELP score
기간: Month 21
|
percentage (%)
|
Month 21
|
|
Predictive values of FRENCH HELP score on miscarriage
기간: Month 21
|
Classed as pregnancy loss before 15 weeks of gestation
|
Month 21
|
|
Predictive values of PUQE score on miscarriage
기간: Month 21
|
Classed as pregnancy loss before 15 weeks of gestation
|
Month 21
|
|
Newborn small for gestational age
기간: At birth (Max 9 months)
|
Classed as birth weight < 10th percentile
|
At birth (Max 9 months)
|
|
Preterm birth
기간: At birth (Max 37 weeks)
|
Classed as delivery before 37 weeks of gestation
|
At birth (Max 37 weeks)
|
|
Gestational hypertension
기간: Before birth (max 9 months)
|
Classed as blood pressure >140 mmHg systolic and/or 90 mmHg diastolic occurring after 20 weeks of gestation
|
Before birth (max 9 months)
|
|
Pre-eclampsia
기간: Before birth (max Month 9)
|
Classed as gestational hypertension and proteinuria >0.3 g/24 hours
|
Before birth (max Month 9)
|
|
Labor characteristics
기간: At birth (Max Month 9)
|
Classed as: spontaneous labor, induction, cesarean section, instrumental delivery, postpartum hemorrhage
|
At birth (Max Month 9)
|
|
Fetal heart rate abnormalities during labor
기간: At birth (max month 9)
|
Yes/no
|
At birth (max month 9)
|
|
Birth weight
기간: At birth (max 9 months)
|
grams
|
At birth (max 9 months)
|
|
newborn Apgar score < 7
기간: At birth (max 9 months)
|
Yes/no
|
At birth (max 9 months)
|
|
Umbilical cord blood pH
기간: At birth (max 9 months)
|
At birth (max 9 months)
|
|
|
Umbilical cord blood PCO2
기간: At birth (max 9 months)
|
mmHg
|
At birth (max 9 months)
|
|
Umbilical cord blood PO2
기간: At birth (max 9 months)
|
mmHg
|
At birth (max 9 months)
|
|
lactate levels in umbilical arterial blood
기간: At birth (max 9 months)
|
mmol/L
|
At birth (max 9 months)
|
|
newborns transferred to a neonatal unit
기간: At birth (max 9 months)
|
Yes/no
|
At birth (max 9 months)
|
|
presence of a congenital malformation
기간: At birth (max 9 months)
|
Yes/no
|
At birth (max 9 months)
|
|
presence of depression
기간: Month 9
|
Measured using the Edinburgh Postnatal Depression Scale - 10 items rated on a scale of 0 to 3, resulting in a total score ranging from 0 to 30.
|
Month 9
|
|
Convergent validity of FRENCH HELP against PUQE score
기간: Month 21
|
PUQE score - 3 questions regarding nausea, vomiting, and retching, scored from 1 to 15, where score is ≥ 13 is classified as severe.
|
Month 21
|
|
Convergent validity of FRENCH HELP against WHOQOL quality-of-life score
기간: Month 21
|
WHOQOL-100 questionnaire - 26 questions measuring four domains: physical health, mental health, social relationships, and environment.
Responses to each item are provided using a 5-point Likert scale ranging from 1 (e.g., "Not at all") to 5 (e.g., "Extremely"); these scores are summed and transformed to correspond to a scale ranging from 0 ("poor health-related quality of life") to 100 ("excellent health-related quality of life").
|
Month 21
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Stephanie Huberlant, Centre Hospitalier Universitaire de Nîmes
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- AOI GCS/2025/S
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .